Study on the material basis of efficacy of Zhenyang jiuxin decoction for the treatment of chronic heart failure ZHAO Zhongkai，WANG Xu，YANG Jia，ZHAO Dantong，WU Yanqiu，CAO Peizhen，RONG Rong，SUN Qihui （1679） Study on the improvement mechanism of Bushen anzhi decoction on anxiety and insomnia in rats with kidney failing to store spirit
- VernacularTitle:补肾安志方对肾不藏志不寐大鼠焦虑失眠的改善机制研究
- Author:
Zhenhui LI
1
;
Xingping ZHANG
1
;
Xu CHEN
1
;
Haiming LI
1
;
Guangke ZUO
1
;
Hailong ZHU
1
;
Ruining LIANG
2
;
Miao WANG
1
Author Information
1. Fourth Clinical Medical College，Xinjiang Medical University，Urumqi 830099，China
2. College of Traditional Chinese Medicine，Xinjiang Medical University，Urumqi 830017，China;Xinjiang Key Laboratory for Research of Neurological Diseases，Urumqi 830063，China
- Publication Type:Journal Article
- Keywords:
Bushen anzhi decoction;
kidney failing to store spirit;
insomnia;
untargeted metabolomics;
differential metabolites
- From:
China Pharmacy
2026;37(13):1685-1690
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the intervention mechanism of Bushen anzhi decoction （BSAZD） in rats with insomnia induced by kidney failing to store spirit. METHODS A total of 36 SD rats were randomly divided into normal group （normal saline）， model group （normal saline）， eszopiclone group （positive control group， 0.27 mg/kg）， and low-， medium- and high-dose BSAZD groups （5.85， 11.70， 23.40 g/kg）， with 6 rats in each group. Except for the normal group， rats in the remaining groups were subjected to combined administration of D-galactose and DL-4-chlorophenylalanine to establish the rat model of insomnia due to kidney failing to store spirit. After successful modeling， corresponding liquid medicine or normal saline was intragastrically administered once daily for 14 consecutive days. After the last administration， behavioral indicators and hippocampal histopathological morphology of rats were detected. Untargeted metabolomics was adopted to screen serum differential metabolites and enrich relevant signaling pathways. RESULTS Compared with the model group， the high-dose BSAZD group exhibited significantly increased open arm entries ， open arm time and sleep time （ P ＜0.05）， accompanied by markedly decreased closed arm entries， closed arm time and sleep latency （ P ＜0.05）. Hippocampal neurons in the high-dose BSAZD group were arranged regularly， and the size， morphology and location of cell nuclei were nearly normal. Untargeted metabolomics analysis identified oxidized glutathione， glutamate and other differential metabolites in serum of rats in the high-dose BSAZD group； these differential metabolites were mainly enriched in GABAergic synapse， glutamatergic synapse， cAMP signaling pathway and 2-oxocarboxylic acid metabolism pathway. CONCLUSIONS BSAZD can improve sleep quality， relieve anxiety-like behaviors in rats with insomnia due to kidney failing to store spirit. Its therapeutic mechanism may be associated with regulating GABAergic and glutamatergic synaptic pathways to restore neurotransmitter balance and further alleviate oxidative stress injury， modulating the cAMP signaling pathway to facilitate neural repair， and intervening the 2-oxocarboxylic acid metabolism pathway to optimize energy supply.
